116 related articles for article (PubMed ID: 10664629)
1. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers.
Kawanishi K; Doki Y; Shiozaki H; Yano M; Inoue M; Fukuchi N; Utsunomiya T; Watanabe H; Monden M
Am J Clin Pathol; 2000 Feb; 113(2):266-74. PubMed ID: 10664629
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of the autocrine motility factor receptor correlates with poor prognosis and promotes metastasis in gastric carcinoma.
Huang Z; Zhang N; Zha L; Mao HC; Chen X; Xiang JF; Zhang H; Wang ZW
Asian Pac J Cancer Prev; 2014; 15(2):989-97. PubMed ID: 24568530
[TBL] [Abstract][Full Text] [Related]
3. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
Taniguchi K; Yonemura Y; Nojima N; Hirono Y; Fushida S; Fujimura T; Miwa K; Endo Y; Yamamoto H; Watanabe H
Cancer; 1998 Jun; 82(11):2112-22. PubMed ID: 9610690
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma.
Endo K; Shirai A; Furukawa M; Yoshizaki T
Hum Pathol; 2006 Aug; 37(8):1111-6. PubMed ID: 16867875
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma.
Wang W; Yang LY; Yang ZL; Peng JX; Yang JQ
Dig Dis Sci; 2007 Mar; 52(3):770-5. PubMed ID: 17265125
[TBL] [Abstract][Full Text] [Related]
6. Expression of autocrine motility factor receptor in cutaneous malignant melanoma.
Nagai Y; Ishikawa O; Miyachi Y; Watanabe H
Dermatology; 1996; 192(1):8-11. PubMed ID: 8832943
[TBL] [Abstract][Full Text] [Related]
7. Re-expression of the cadherin-catenin complex in lymph nodes with metastasis in advanced gastric cancer: the relationship with patient survival.
Liu J; Ikeguchi M; Nakamura S; Kaibara N
J Exp Clin Cancer Res; 2002 Mar; 21(1):65-71. PubMed ID: 12071532
[TBL] [Abstract][Full Text] [Related]
8. The significances of lymph node micrometastasis and its correlation with E-cadherin expression in pT1-T3N0 gastric adenocarcinoma.
Kim JH; Park JM; Jung CW; Park SS; Kim SJ; Mok YJ; Kim CS; Chae YS; Bae JW
J Surg Oncol; 2008 Feb; 97(2):125-30. PubMed ID: 18095267
[TBL] [Abstract][Full Text] [Related]
9. Autocrine motility factor receptor expression in patients with stage I non-small cell lung cancer.
Kara M; Ohta Y; Tanaka Y; Oda M; Watanabe Y
Ann Thorac Surg; 2001 Mar; 71(3):944-8. PubMed ID: 11269478
[TBL] [Abstract][Full Text] [Related]
10. Autocrine motility factor receptor expression implies an unfavourable prognosis in resected stage I pulmonary adenocarcinomas.
Kaynak K; Kara M; Oz B; Akgoz B; Sar M; Raz A
Acta Chir Belg; 2005 Aug; 105(4):378-82. PubMed ID: 16184720
[TBL] [Abstract][Full Text] [Related]
11. Autocrine motility factor receptor: a clinical review.
Chiu CG; St-Pierre P; Nabi IR; Wiseman SM
Expert Rev Anticancer Ther; 2008 Feb; 8(2):207-17. PubMed ID: 18279062
[TBL] [Abstract][Full Text] [Related]
12. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder.
Korman HJ; Peabody JO; Cerny JC; Farah RN; Yao J; Raz A
J Urol; 1996 Jan; 155(1):347-9. PubMed ID: 7490884
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of autocrine motility factor receptor expression by colorectal cancer and lymph node metastases.
Halwani Y; Kojic LD; Chan SK; Phang TP; Masoudi H; Jones SJ; Nabi IR; Wiseman SM
Am J Surg; 2015 May; 209(5):884-9; discussion 889. PubMed ID: 25852009
[TBL] [Abstract][Full Text] [Related]
14. Motility- and adhesion factors in bladder carcinoma.
Otto T; Goepel M; Enzwi SM; Meyer-Schwickerath M; Rübben H
Investig Urol (Berl); 1994; 5():80-4. PubMed ID: 7719326
[No Abstract] [Full Text] [Related]
15. Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.
Sato Y; Inokuchi M; Takagi Y; Otsuki S; Fujimori Y; Yanaka Y; Kobayashi K; Higuchi K; Kojima K; Kawano T
J Clin Pathol; 2015 Oct; 68(10):795-801. PubMed ID: 26043748
[TBL] [Abstract][Full Text] [Related]
16. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas.
Otto T; Birchmeier W; Schmidt U; Hinke A; Schipper J; Rübben H; Raz A
Cancer Res; 1994 Jun; 54(12):3120-3. PubMed ID: 8205527
[TBL] [Abstract][Full Text] [Related]
17. Analysis of a cytoskeleton-associated kinase PEAK1 and E-cadherin in gastric cancer.
Guo Q; Qin W; Li B; Yang H; Guan J; Liu Z; Li S
Pathol Res Pract; 2014 Dec; 210(12):793-8. PubMed ID: 25445115
[TBL] [Abstract][Full Text] [Related]
18. Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer.
Jiang WG; Raz A; Douglas-Jones A; Mansel RE
J Histochem Cytochem; 2006 Feb; 54(2):231-41. PubMed ID: 16204225
[TBL] [Abstract][Full Text] [Related]
19. Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases.
He Q; Chen J; Lin HL; Hu PJ; Chen MH
Chin Med J (Engl); 2007 Sep; 120(17):1498-504. PubMed ID: 17908458
[TBL] [Abstract][Full Text] [Related]
20. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
